Iluvien investigated for dry AMD

Article

A pilot study using Iluvien (an intravitreal insert delivering fluocinolone acetonide) to treat geographic atrophy secondary to age-related macular degeneration (AMD) has begun enrolling patients, according to a statement from Alimera Sciences Inc, the developer of Iluvien.

A pilot study using Iluvien (an intravitreal insert delivering fluocinolone acetonide) to treat geographic atrophy secondary to age-related macular degeneration (AMD) has begun enrolling patients, according to a statement from Alimera Sciences Inc, the developer of Iluvien.

The pilot study will assess the safety and efficacy of Iluvien 0.23 and 0.45 µg daily - intended to manage oxidative stress and arrest development of bilateral geographic atrophy - and compare the results with placebo. The study was initiated because miniaturized Iluvien was found to inhibit retinal degeneration in two animal models.

Iluvien, which is implanted during an out-patient procedure with a 25 G inserter, is currently in Phase III testing for the treatment of diabetic macular oedema (DME).

Related Videos
Ramin Tadayoni, MD, speaks with Sheryl Stevenson
Jennifer I. Lim, MD, FARVO, FASRS, Director of Retina Service, University of Illinois at Chicago
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center
Carl D. Regillo, MD, FACS, FASRS, Chief of Retina Service, Wills Eye Hospital, Philadelphia, PA
Arshad Khanani, MD, MA FASRS, on a virtual call
Diana Do, MD, Professor of Ophthalmology, Byers Eye Institute, Stanford University, discusses the PHOTON study results as presented AAO
Penny A Asbell, MD, FACS speaks at the 2023 AAO meeting
© 2024 MJH Life Sciences

All rights reserved.